Global Embolotherapy Market is valued approximately at USD XX billion in 2021 and is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2022-2029. Embolotherapy is a minimally invasive medical procedure that involves the use of embolic agents to block blood vessels or blood flow in order to treat a variety of medical conditions. Embolic agents can be solid particles, gels, or liquids that are injected directly into a blood vessel, causing the vessel to clot and preventing blood from flowing to a specific area of the body. Embolotherapy is used to treat a variety of conditions, including uterine fibroids, liver tumors, aneurysms, and vascular malformations. The technique is minimally invasive than traditional surgery and can be performed on an outpatient basis in some cases, with shorter recovery times and fewer complications. The key factor driving the market growth is rising demand for the minimally invasive surgical procedures, favorable reimbursement scenario for minimally invasive surgeries and growing technological advancement in embolotherapy devices.

The rising demand for minimally invasive surgical procedures is anticipated to support the growth of the embolotherapy market. Embolotherapy is a minimally invasive technique used to treat a wide range of medical conditions, including cancer, uterine fibroids, aneurysms, and vascular malformations. According to Statista, in 2019, the minimally invasive surgery market globally was valued USD 20.5 billion and it is anticipated to reach USD 44.04 billion by 2030. As a result, the rising demand for the minimally invasive surgical procedures is anticipated to propel the market growth. Additionally, the growing target patient population and rising funding & investment by government and private organizations for the medical and health care facility development is anticipated to create the lucrative opportunity for the market during projected period. However, the lack of sufficient evidence & unfavorable regulatory scenario, and strong market positioning of alternative therapies stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Embolotherapy Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominates the market holding the largest market share, owing to the presence of key market players, favorable reimbursement policies, and growing investments for the healthcare facility development. Whereas, Asia Pacific is anticipated to exhibit fastest growing region during forecasted period over the forecast period, owing to factors such as booming medical tourism, developing healthcare network and increasing research and development activities in the region would create lucrative growth prospects for the Embolotherapy market across Asia Pacific region.

Major market player included in this report are:
Imbiotechnologies Ltd.
Johnson & Johnson
Kaneka Corporation
Medtronic Plc
Meril Life Sciences Pvt. Ltd.
Merit Medical Systems, Inc.
Penumbra, Inc.
Simbionix USA Corporation
Sirtex Medical Limited
Stryker Corporation
Recent Developments in the Market:
- In 2021, Terumo Corporation has received FDA approval for the PMA Supplement for the WEB 17 System, a novel component of the WEB Aneurysm Embolisation System for the treatment of intracranial wide-neck bifurcation aneurysms.

Global Embolotherapy Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Product, Procedure, Disease indication, End user, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*


The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product:
Embolic Agents
Support Devices
By Procedure:
Transcatheter Arterial Embolization (TAE)
Selective Internal Radiation Therapy (SIRT)
Trans arterial Chemoembolization (TACE)
By Disease indication:
Cancer
Peripheral Vascular Disease
Neurological Diseases
Urological
Nephrological Disorders
Gastrointestinal Disorders
By End user:
Hospitals
Clinics
Ambulatory Surgery Centers
Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World